Chronic cough, defined as a cough persisting for more than eight weeks, presents a diagnostic challenge to clinicians due to its multifactorial etiology. This article outlines a comprehensive approach to diagnosing and treating this common yet perplexing condition.
Initial evaluation should focus on common causes such as gastroesophageal reflux disease (GERD), asthma, and upper airway cough syndrome (UACS). History taking and physical examination can guide further investigations, including chest radiography, spirometry, and testing for GERD. If these investigations are inconclusive, rarer causes such as bronchiectasis, lung cancer, and non-asthmatic eosinophilic bronchitis should be considered.
Treatment should be tailored to the underlying cause. In cases of GERD, proton pump inhibitors and lifestyle modifications are first-line therapies. For asthma-related cough, inhaled corticosteroids and bronchodilators are recommended. Antihistamines and decongestants can alleviate UACS symptoms. If the cough remains unresponsive, referral to a specialist may be necessary for further diagnostic testing and treatment.
A multidisciplinary approach involving pulmonologists, gastroenterologists, and otolaryngologists can provide a comprehensive evaluation and treatment plan. This collaborative approach can lead to improved patient outcomes and satisfaction.
The development of new diagnostic tools and treatments, including molecular markers and targeted therapies, may revolutionize the management of chronic cough. Further research is needed to validate these promising advances.
Chronic cough is a complex condition requiring a systematic and comprehensive approach to diagnosis and treatment. By considering common and rarer causes, tailoring treatment to the underlying etiology, and utilizing a multidisciplinary team, clinicians can effectively manage this challenging condition. Continued research into novel diagnostic and therapeutic strategies will further enhance our ability to treat chronic cough.
1.
Injecting PD-1 Drug Directly Into Oral Precancers Shrinks Lesions
2.
Sevabertinib Approved for First-Line Mutated NSCLC
3.
After three years, responses to mounetuzumab in follicular lymphoma are still stable.
4.
FDA Bans Red Dye No. 3 From Foods, Ingested Drugs
5.
AI can identify women at risk of breast cancer years in advance: Study
1.
Revolutionizing Cancer Treatment: Advances in Immunotherapy and Cell Therapy
2.
Pediatric Tumor Microenvironment Evolution: Mechanisms, Clinical Impact, and Therapeutic Implications
3.
Hematopoietic Stem Cell Activity Biomarkers in Aging
4.
Bone-Marrow Immune Cell Competition: Mechanisms, Clinical Implications, and Emerging Therapeutic Perspectives
5.
The Truth About TAR Syndrome: Understanding the Rare Genetic Disorder
1.
International Conference on Innovations in Critical Care for Oncology and Cardiology
2.
International Conference on Oncology, Cardiology and Critical Care Policy
3.
International Conference on Oncology, Cancer Prevention and Public Health
4.
International Conference on Cancer Nursing and Rehabilitation Strategies
5.
International Conference on Best Practices in Oncology, Cardiology and Critical Care
1.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part VIII
2.
A New Era in Managing Cancer-Associated Thrombosis
3.
Emerging Concepts in Hematology
4.
The Reign of the CROWN Trial and the Dawn of a New Era in Frontline Management- Further Discussion
5.
An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- Panel Discussion III
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation